Most Read Articles
11 May 2020
This second issue revisits the impact EMPA-REG OUTCOME had on clinical practice and helps readers discover how it gives life back to patients through its cardiovascular indication. Learn how it was approved and the possible mechanisms for its cardiovascular benefits.
Pearl Toh, 15 Oct 2020
Cycling was associated with reduced risk for both all-cause and cardiovascular (CV) mortality in people with diabetes, according to a study presented at EASD 2020 Meeting — suggesting that cycling could be encouraged as an activity to prevent deaths in this population who are known to have a higher mortality risk than the general public.
Stephen Padilla, 22 Jul 2019
Zinc supplementation significantly lowers key glycaemic indicators, particularly fasting glucose (FG) in individuals with diabetes and in those who received an inorganic supplement, results of a systematic review and meta-analysis have shown.
Elaine Soliven, 15 Oct 2020

Higher levels of exercise appear to be associated with a lower risk of all-cause mortality in adults with type 2 diabetes (T2D) compared with no exercise at all, according to a study presented at EASD 2020.

Dapagliflozin delivers positive impact on cardiorenal axis in T2D patients

28 Aug 2020

Treatment with the SGLT2 inhibitor dapagliflozin appears to confer beneficial effects on systemic and renal haemodynamic functions independently and beyond glucose lowering in individuals with type 2 diabetes (T2D), a study has found.

Forty-four T2D patients were randomly assigned to 12 weeks of dapagliflozin 10 mg/day or gliclazide 30 mg/day treatment. The investigators noninvasively measured systemic haemodynamic function, autonomic nervous system activity, and vascular stiffness. They also assessed renal haemodynamics, glomerular filtration rate (GFR), and effective renal plasma flow with gold-standard urinary clearances of inulin or iohexol and para-aminohippuric acid, respectively.

The associations between dapagliflozin-induced changes in cardiovascular and renal variables were then examined via correlation analyses.

Dapagliflozin therapy led to a decrease in stroke volume by 4 percent, cardiac output by 5 percent, vascular stiffness by 11 percent, and mean arterial pressure by 5 percent from baseline, without increasing heart rate or sympathetic activity. At the same time, dapagliflozin reduced GFR by 8 percent.

Although dapagliflozin and gliclazide both improved glycaemic control (–0.5±0.5 percent vs –0.7±0.5 percent; p=0.12), the latter did not any of the above measurements. Moreover, no clear relationship was observed between the dapagliflozin-induced changes in cardiovascular and renal physiology.

“There is a bidirectional relationship between cardiovascular and renal disease,” the investigators said. “The drug-class of SGLT2 inhibitors improves outcomes at both ends of this so called cardiorenal axis.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 May 2020
This second issue revisits the impact EMPA-REG OUTCOME had on clinical practice and helps readers discover how it gives life back to patients through its cardiovascular indication. Learn how it was approved and the possible mechanisms for its cardiovascular benefits.
Pearl Toh, 15 Oct 2020
Cycling was associated with reduced risk for both all-cause and cardiovascular (CV) mortality in people with diabetes, according to a study presented at EASD 2020 Meeting — suggesting that cycling could be encouraged as an activity to prevent deaths in this population who are known to have a higher mortality risk than the general public.
Stephen Padilla, 22 Jul 2019
Zinc supplementation significantly lowers key glycaemic indicators, particularly fasting glucose (FG) in individuals with diabetes and in those who received an inorganic supplement, results of a systematic review and meta-analysis have shown.
Elaine Soliven, 15 Oct 2020

Higher levels of exercise appear to be associated with a lower risk of all-cause mortality in adults with type 2 diabetes (T2D) compared with no exercise at all, according to a study presented at EASD 2020.